James G. McArthur net worth and biography

James McArthur Biography and Net Worth

President and Chief Executive Officer of PepGen

James McArthur currently serves as President and Chief Executive Officer of PepGen and serves on the company’s Board of Directors. James has 25+ years of industry experience, has cofounded five biotechnology companies, three of which were acquired, and has served as a director of two companies through successful initial public offerings. He was founding CEO of Imara, a public company developing therapies for sickle cell disease and beta-thalassemia, co-founder and President of R&D of Cydan, a rare disease accelerator, and founding CSO of Synovex/Adheron, a rheumatology therapy company acquired by Roche. Prior to these companies, James held senior research leadership roles in several pioneering gene and stem cell therapy companies. He was a Venture Partner at RA Capital and an entrepreneur in residence at HealthCare Ventures. James was previously a post-doctoral fellow at MIT and UC Berkeley working with Drs. David Raulet and Nobel Laureate James Allison, before which he received his PhD in Molecular Oncology and BSc in Biochemistry from McGill University.

What is James G. McArthur's net worth?: The estimated net worth of James G. McArthur is at least $253.46 thousand as of April 17th, 2025. Mr. McArthur owns 113,913 shares of PepGen stock worth more than $253,456 as of August 6th. This net worth approximation does not reflect any other investments that Mr. McArthur may own. Learn More about James G. McArthur's net worth.
How do I contact James G. McArthur?: The corporate mailing address for Mr. McArthur and other PepGen executives is , , . PepGen can also be reached via phone at 781-797-0979 and via email at [email protected]. Learn More on James G. McArthur's contact information.
Has James G. McArthur been buying or selling shares of PepGen?: James G. McArthur has not been actively trading shares of PepGen in the last ninety days. Most recently, on Thursday, April 17th, James G. Mcarthur bought 10,000 shares of PepGen stock. The stock was acquired at an average cost of $1.35 per share, with a total value of $13,500.00. Following the completion of the transaction, the chief executive officer now directly owns 113,913 shares of the company's stock, valued at $153,782.55. Learn More on James G. McArthur's trading history.
Are insiders buying or selling shares of PepGen?: During the last year, PepGen insiders bought shares 1 times. They purchased a total of 200,000 shares worth more than $640,000.00. During the last year, insiders at the sold shares 1 times. They sold a total of 1,233 shares worth more than $1,738.53. The most recent insider tranaction occured on May, 21st when insider Kasra Kasraian sold 1,233 shares worth more than $1,738.53. Insiders at PepGen own 1.3% of the company. Learn More about insider trades at PepGen.
Information on this page was last updated on 5/21/2026.

James G. McArthur Insider Trading History at PepGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/17/2025	Buy	10,000	$1.35	$13,500.00	113,913
4/8/2025	Buy	41,500	$1.15	$47,725.00	103,913
11/30/2023	Buy	1,694	$4.17	$7,063.98	1,694
6/7/2023	Sell	8,419	$16.23	$136,640.37
6/5/2023	Sell	500	$16.06	$8,030.00
6/2/2023	Sell	1,800	$16.04	$28,872.00

James G. McArthur Buying and Selling Activity at PepGen

PepGen Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

Today's Range

Now: $2.35

$2.06

$2.39

50 Day Range

MA: $1.82

$1.35

$2.44

2 Week Range

Now: $2.35

$1.01

$7.80

Volume

3,157,325 shs

Average Volume

1,068,324 shs

Market Capitalization

$162.20 million

P/E Ratio

N/A

Dividend Yield